Aetna considers a thermal perfusion probe for monitoring regional cerebral blood flow experimental and investigational because there is insufficient evidence of the clinical value of these approaches in the management of individuals with acute neurological disorders (e.g., head injury, subarachnoid hemorrhage, or following neurosurgery) or for other indications.
See also CPB 0663 - Cerebral Perfusion Studies.Background
Cerebral blood flow (CBF) is essential for normal metabolism of the brain. Ischemic brain injury occurs when CBF is insufficient to meet metabolic demand, which can occur in acute neurological disorders (e.g. head injury, subarachnoid hemorrhage, or following neurosurgery).
Various imaging techniques have been attempted to identify individuals at risk for secondary ischemic brain injury and manage response to therapies. Some of these techniques are still evolving (e.g., stable-xenon-enhanced computed tomography (XeCT), perfusion computed tomography, perfusion magnetic resonance imaging, single photon emission computed tomography (SPECT) and positron emission tomography (PET)). While these techniques can provide regional information about CBF, the data provided is a single snap shot in time. Methods for the continuous measurement of CBF have been investigated and are now commercially available. One such method is a thermal perfusion probe, which is placed intra-cerebrally via a burr hole in the vascular area of interest in the brain. The probe is connected to a monitor that displays CBF data.
The QFlow 500 probe (Hemedex, Inc, Cambridge, MA) is an example of a commercially available thermal perfusion probe that has received 510(k) marketing clearance from the Food and Drug Administration (FDA). It is used along with the Bowman Perfusion Monitor, Model 500 (Hemedex, Inc, Cambridge, MA). According to the manufactures website, one potential application of the device is for monitoring CBF in patients with traumatic brain injury to help identify secondary ischemic injury to the brain. The manufacturer states that, by measuring continuous, real-time CBF, clinicians may identify cerebral edema and measure tissue blood flow response to therapies. Another potential neurological application is monitoring CBF following neurosurgery (e.g., aneurysm and subarachnoid hemorrhage procedures).
Current literature on thermal perfusion probes has focused on their clinical feasibility and technical capabilities. Jaeger et al (2005) measured regional cerebral blood flow (rCBF) using the QFlow in patients with severe subarachnoid hemorrhage (n = 5) and traumatic brain injury (n = 3) and compared these results to brain tissue oxygen measurements (P(ti)O(2)) using the Licox (GMS, Kiel-Mielkendorf, Germany) for an average of 9.6 days. The data indicated a significantcorrelation between CBF and P(ti)O(2) (r = 0.36). After 400 intervals of 30-min duration, the QFlow and the P(ti)O(2) measurements correlated 72 % of the time when P(ti)O(2) changes were greater than 5 mm Hg (r > 0.6). In 19 % of the intervals a statistically significant correlation was observed (r < 0.6). During the remaining 9 %, no correlation was found (r < 0.3). The authors suggested that the level of P(ti)O(2) is predominately determined by rCBF, since changes in P(ti)O(2) were correlated in 90 % of episodes to simultaneous changes of CBF. Phases of non-monitoring were mostly due to fever of the patient, when the system does not allow monitoring to avoid overheating of the cerebral tissue.
Vajkoczy et al (2003) obtained rCBF using thermal-diffusion (TD) microprobes to prospectively diagnose symptomatic vasospasm in 14 patients with high-grade subarachnoid hemorrhage (SAH) who underwent early clip placement for anterior circulation aneurysms. The TD microprobes were implanted into the white matter of vascular territories that were deemed at risk for developing symptomatic vasospasm. Data on arterial blood pressure, intracranial pressure, cerebral perfusion pressure, rCBF, cerebrovascular resistance (CVR), and blood flow velocities were collected at the patient's bedside. The diagnosis of symptomatic vasospasm was based on the manifestation of a delayed ischemic neurological deficit and/or a reduced territorial level of CBF as assessed using stable XeCT scanning in combination with vasospasm demonstrated by angiography. Bedside monitoring of TD-rCBF and CVR allowed the detection of symptomatic vasospasm. In the 10 patients with vasospasm, the TD-rCBF decreased from 21 +/- 4 to 9 +/- 1 ml/100 g/min), whereas in the 4 other patients the TD-rCBF value remained unchanged (mean TD-rCBF = 25 +/- 4 compared with 21 +/- 4 ml/100 g/min). Based on a comparison of the results of TD-rCBF and Xe-enhanced CT studies, as well as the calculation of sensitivities, specificities, predictive values, and likelihood ratios, the investigators identified a TD-rCBF value of 15 ml/100 g/min as a reliable cutoff for the diagnosis of symptomatic vasospasm. In addition, the investigators found that TD flowmetry was characterized by a more favorable diagnostic reliability than transcranial Doppler ultrasonography. The authors concluded that TD flowmetry represents a promising method for the bedside monitoring of patients with SAH to detect symptomatic vasospasm.
Current literature on thermal perfusion probes has focused on their feasibility and technical capabilities. Prospective clinical outcome studies are needed to determine their clinical value over other standard methods of identifying individuals at risk for secondary ischemic brain injury (e.g., head injury, subarachnoid hemorrhage, or following neurosurgery) and in monitoring response to therapies.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015:|
|Other CPT codes related to the CPB:|
|0042T||Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time|
|61000 - 64999||Nervous System/Surgery|
|ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):|
|E75.00 - E75.19, E75.23
E75.25, E75.29, E75.4
|Disorders of sphingolipid metabolism and other lipid storage disorders|
|G00.0 - G09||Inflammatory diseases of the central nervous system|
|G11.0 - G12.9
|Systemic atrophies primarily affecting the central nervous system|
|G20 - G26||Extrapyramidal and movement disorders|
|G30.0 - G32.8||Other degenerative diseases of the nervous system|
|G35 - G43.919||Demyelinating diseases of the cental nervous system and episodic and paroxysmal disorders|
|G45.0 - G45.9||Transient cerebral ischemic attacks and related syndromes|
|G46.0 - G46.8||Vascular syndromes of brain in cerebrovascular diseases|
|G80.0 - G83.9||Cerebral palsy and other paralytic syndromes|
|G90.01 - G91.9, G93.7, G93.89, G93.9
G94, G95.0 - G95.9, G99.0, G99.2
|Other disorders of the nervous system|
|I60.00 - I66.9, I67.1 - I67.2
I67.4 - I69.998
|S02.0xx+ - S02.413+
S02.60x+ - S02.92x+
|Fracture of skull and facial bones, with or without intracranial injury|
|S06.0x0+ - S06.9x9+||Intracranial injury, excluding those with skull fracture|
|Z13.850||Encounter for screening for traumatic brain injury|
|Z13.858||Encounter for screening for other nervous system disorders|